Merit Medical Systems (NASDAQ:MMSI) Downgraded by Wells Fargo & Company to Equal Weight

Wells Fargo & Company cut shares of Merit Medical Systems (NASDAQ:MMSI) from an overweight rating to an equal weight rating in a research report released on Thursday, MarketBeat reports. Wells Fargo & Company currently has $78.00 price target on the medical instruments supplier’s stock, down from their previous price target of $95.00.

A number of other brokerages have also commented on MMSI. Zacks Research lowered shares of Merit Medical Systems from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 18th. Canaccord Genuity Group increased their target price on Merit Medical Systems from $93.00 to $99.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Weiss Ratings restated a “hold (c)” rating on shares of Merit Medical Systems in a research report on Monday, December 29th. Robert W. Baird set a $108.00 price objective on Merit Medical Systems in a report on Tuesday, December 16th. Finally, Needham & Company LLC reduced their price objective on Merit Medical Systems from $108.00 to $101.00 and set a “buy” rating on the stock in a research report on Wednesday. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, Merit Medical Systems has an average rating of “Moderate Buy” and an average target price of $103.33.

Merit Medical Systems Price Performance

Shares of NASDAQ MMSI opened at $78.02 on Thursday. The stock’s 50-day simple moving average is $83.73 and its two-hundred day simple moving average is $84.89. Merit Medical Systems has a twelve month low of $76.68 and a twelve month high of $107.27. The firm has a market capitalization of $4.64 billion, a P/E ratio of 36.80, a P/E/G ratio of 2.15 and a beta of 0.61. The company has a quick ratio of 2.86, a current ratio of 4.34 and a debt-to-equity ratio of 0.46.

Merit Medical Systems (NASDAQ:MMSI) last issued its quarterly earnings data on Tuesday, February 24th. The medical instruments supplier reported $1.04 EPS for the quarter, topping the consensus estimate of $0.96 by $0.08. The company had revenue of $393.94 million during the quarter, compared to analyst estimates of $390.77 million. Merit Medical Systems had a return on equity of 13.82% and a net margin of 8.48%.Merit Medical Systems’s revenue was up 10.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.93 earnings per share. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. As a group, equities analysts anticipate that Merit Medical Systems will post 3.37 EPS for the current fiscal year.

Institutional Investors Weigh In On Merit Medical Systems

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MMSI. Los Angeles Capital Management LLC bought a new stake in Merit Medical Systems in the 4th quarter worth $25,000. Maseco LLP purchased a new stake in shares of Merit Medical Systems during the fourth quarter worth about $26,000. Torren Management LLC purchased a new stake in shares of Merit Medical Systems during the fourth quarter worth about $38,000. Salomon & Ludwin LLC bought a new stake in shares of Merit Medical Systems in the third quarter worth about $37,000. Finally, Covestor Ltd increased its holdings in Merit Medical Systems by 252.6% during the 4th quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier’s stock valued at $41,000 after purchasing an additional 336 shares during the period. 99.66% of the stock is currently owned by institutional investors.

Key Stories Impacting Merit Medical Systems

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Q4 results beat expectations: EPS and revenue topped consensus, margins expanded driven by Cardiovascular strength and solid U.S. & EMEA sales — a fundamental driver supporting the stock. Merit Medical Q4 Earnings & Revenues Beat Estimate, Margins Expand
• Positive Sentiment: Barrington Research raised its price target to $109 and maintained an “outperform” rating, signaling bullish analyst conviction that the company can deliver upside from current levels. Barrington Research raises PT to $109
• Positive Sentiment: Management projects 6%–8% revenue growth for 2026 and is divesting the DualCap business to focus on strengthening global platforms—this strategic clarity and growth guide support medium‑term revenue expansion. Merit projects 6%-8% revenue growth for 2026 while divesting
• Neutral Sentiment: Earnings call presentation and detailed slides are available for review — useful for investors digging into segment performance and margin drivers but not new market-moving information on their own. Q4 results presentation
• Neutral Sentiment: Analyst notes and metric comparisons provide context on how the quarter stacks vs. estimates and prior-year numbers—helpful for modeling but not immediately directional. Zacks: Q4 key metrics vs estimates
• Neutral Sentiment: General earnings highlights and recap pieces summarize the beat and guidance for investors who want a quick read. Yahoo Finance earnings highlights
• Neutral Sentiment: Needham kept a Buy rating, citing the strong quarter and outlook, but trimmed its price target to $101 — a mixed signal (positive conviction on fundamentals, smaller near-term upside in the analyst view). TipRanks: Needham maintains Buy, lowers PT
• Negative Sentiment: Wells Fargo downgraded MMSI from Overweight to Equal Weight and cut its price target to $78, signaling reduced near-term conviction and adding selling pressure. Wells Fargo downgrades to Equal Weight

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.